-
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)
The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
Transformation Protocol – Sample Transformation Protocols(Post)Introduction Transformation of bacteria with plasmids is not only of note for bacterial studies but also can be used for gene expression studies in mammalian cells. Most plasmids are of bact
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Apamistamab: Advancing Leukemia Treatment through Targeted Radioimmunotherapy(Post)Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the
Adaptive immune system molecules(Page) Hybridoma Technology: Revolutionizing Antibody Production(Post)Immunology · Antibody ProductionHybridoma Technology: How Monoclonal Antibodies Are MadeHybridoma technology, pioneered by Georges Köhler and César Milstein in 1975, is the method that made monoclonal
Validation of MycoGenie Rapid Mycoplasma Detection Kit - A highly sensitive visual determination method for Mycoplasma detection.(Post)The MycoGenie Rapid Mycoplasma Detection Kit enables the detection of 28 Mycoplasma species in under 1 hour using a simple visual determination method, eliminating the need for expensive
Amino Acid and Protein Assays(Page) Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Acute Lymphoblastic Leukaemia Review | Assay Genie(Post)Incidence rate of Acute Lymphoblastic Leukaemia Acute lymphoblastic leukaemia (ALL) is one of the most common malignant diseases diagnosed in children. It
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Immuno Oncology: If cancer was a pathogen, would a vaccine be able to destroy it?(Post)Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the
The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread(Post)The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread In the intricate battlefield of the human body, the immune system’s foot soldiers, neutrophils, have long been re
Microtubule and Mitosis review(Post)Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
CD4 T-Helper Differentiation: Th1, Th2, Th17, Treg and Tfh(Post)The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C
CXC Chemokine Family(Post)In the realm of immunology, CXCL chemokines emerge as fascinating conductors. These small proteins, marked by their CXC motif, wield considerable influence over our immune responses and a ra
Allorecognition, Transplant Rejection & GvHD(Page) Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu